Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Stamford

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|May 26, 2018
Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 DiabetesSanthosh F Neelamkavil, Andrew W Stamford, Timothy Kowalski, et al.
Experimental Neurology|July 27, 2010
Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disordersRobert A Hodgson, Paul J Bedard, Geoffrey B Varty, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2019
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cellsEdouard Mullarky, Jiayi Xu, Anita D Robin, et al.
ACS Medicinal Chemistry Letters|March 18, 2022
A Chemical Strategy toward Novel Brain-Penetrant EZH2 InhibitorsRui Liang, Daisuke Tomita, Yusuke Sasaki, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunctionDmitri A Pissarnitski, Theodros Asberom, Craig D Boyle, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2009
Diaryl piperidines as CB1 receptor antagonistsJack D Scott, Sarah W Li, Hongwu Wang, et al.
ACS Medicinal Chemistry Letters|April 17, 2024
Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable <i>In Vivo</i> Studies: Discovery of TDI-11055Mayako Michino, Tanweer A Khan, Michael W Miller, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2007
Discovery of novel orally active ureido NPY Y5 receptor antagonistsGuoqing Li, Andrew W Stamford, Ying Huang, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitorsYuguang Wang, Samuel Chackalamannil, Zhiyong Hu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2009
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionRobert A Hodgson, Rosalia Bertorelli, Geoffrey B Varty, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|May 26, 2018
Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 DiabetesSanthosh F Neelamkavil, Andrew W Stamford, Timothy Kowalski, et al.
Experimental Neurology|July 27, 2010
Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disordersRobert A Hodgson, Paul J Bedard, Geoffrey B Varty, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2019
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cellsEdouard Mullarky, Jiayi Xu, Anita D Robin, et al.
ACS Medicinal Chemistry Letters|March 18, 2022
A Chemical Strategy toward Novel Brain-Penetrant EZH2 InhibitorsRui Liang, Daisuke Tomita, Yusuke Sasaki, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunctionDmitri A Pissarnitski, Theodros Asberom, Craig D Boyle, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2009
Diaryl piperidines as CB1 receptor antagonistsJack D Scott, Sarah W Li, Hongwu Wang, et al.
ACS Medicinal Chemistry Letters|April 17, 2024
Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable <i>In Vivo</i> Studies: Discovery of TDI-11055Mayako Michino, Tanweer A Khan, Michael W Miller, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2007
Discovery of novel orally active ureido NPY Y5 receptor antagonistsGuoqing Li, Andrew W Stamford, Ying Huang, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2002
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitorsYuguang Wang, Samuel Chackalamannil, Zhiyong Hu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2009
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionRobert A Hodgson, Rosalia Bertorelli, Geoffrey B Varty, et al.
Pageof 4